Search

for
Search:

Research

2 / 1000+ results

research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China

1 citations , May 2025 in “BMC Cancer”

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

June 2024 in “Journal of Clinical Oncology”

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

View more "dalpiciclib" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →